Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
PURPOSE: Epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (TKIs) are standard first-line therapy for EGFR -mutant, metastatic non–small cell lung cancer (NSCLC); however, most patients experience disease progression. We report results from the randomized, double-blind, phase III KEYNOTE-789 study of pemetrexed and platinum–based chemotherapy with or without pembrolizumab for TKI-resistant, EGFR -mutant, metastatic nonsquamous NSCLC (ClinicalTrials.gov identifier: NCT03515837 ). METHODS: Adults with pathologically confirmed stage IV nonsquamous NSCLC, documented DEL19 or L858R EGFR mutation, and progression after EGFR-TKI treatment were randomly assigned 1:1 to 35 cycles of pembrolizumab 200 mg or placebo once every 3 weeks plus four cycles of pemetrexed and carboplatin or cisplatin once every 3 weeks and then maintenance pemetrexed. Dual primary end points were progression-free survival (PFS) and overall survival (OS). Final PFS testing was completed at the second interim analysis (IA2; data cutoff, December 3, 2021); OS was tested at final analysis (FA; data cutoff, January 17, 2023). Efficacy boundaries were one-sided P = .0117 for PFS and OS. RESULTS: Four hundred ninety-two patients were randomly assigned to pembrolizumab plus chemotherapy (n = 245) or placebo plus chemotherapy (n = 247). At IA2, the median PFS was 5.6 months for pembrolizumab plus chemotherapy versus 5.5 months for placebo plus chemotherapy (hazard ratio [HR], 0.80 [95% CI, 0.65 to 0.97]; P = .0122). At FA, the median OS was 15.9 versus 14.7 months, respectively (HR, 0.84 [95% CI, 0.69 to 1.02]; P = .0362). Grade ≥3 treatment-related adverse events occurred in 43.7% of pembrolizumab plus chemotherapy recipients versus 38.6% of placebo plus chemotherapy recipients. CONCLUSION: Addition of pembrolizumab to chemotherapy in patients with TKI-resistant, EGFR -mutant, metastatic nonsquamous NSCLC did not significantly prolong PFS or OS versus placebo plus chemotherapy in KEYNOTE-789.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Self-citationPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Self-citationPembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
Self-citationiRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis
Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.007 · Cited by 839
Self-citationLee, C. K., Man, J., Lord, S., Cooper, W., Links, M., Gebski, V., Herbst, R. S., Gralla, R. J., Mok, T., & Yang, J. C.-H. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4427 · Cited by 598
Self-citationDong, Z.-Y., Zhang, J.-T., Liu, S.-Y., Su, J., Zhang, C., Xie, Z., Zhou, Q., Tu, H.-Y., Xu, C.-R., Yan, L.-X., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356145 · Cited by 440
Self-citation
Cited by
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Self-citationAdvances and future directions in ROS1 fusion-positive lung cancer
Boulanger, M. C., Schneider, J. L., & Lin, J. J. (2024) · The Oncologist · doi:10.1093/oncolo/oyae205 · Cited by 38
HARMONi-A Study Investigators, Fang, W., Zhao, Y., Luo, Y., Yang, R., Huang, Y., He, Z., Zhao, H., Li, M., Li, K., et al. (2026) · JAMA · doi:10.1001/jama.2026.7745 · Cited by 8
Self-citation
Metadata
- Authors
- Yang, J. C.-H., Lee, D. H., Lee, J.-S., Fan, Y., de Marinis, F., Iwama, E., Inoue, T., Rodríguez-Cid, J., Zhang, L., Yang, C.-T., de la Mora Jimenez, E., Zhou, J., Pérol, M., Lee, K. H., Vicente, D., Ichihara, E., Riely, G. J., Luo, Y., Chirovsky, D., Pietanza, M. C., Bhagwati, N., Lu, S., Joseph Boyer, M., Hui, R., Wong, M., Mant, A., Parente, P., John, T., Parakh, S., Castro, G., Werutsky, G., de Azevedo, S. J., Andre Franke, F., De Almeida Rego, J. B., Martins De Marchi, P. R., Dix Junqueira, G., Maris Peria, F., Brust, L., Cheema, P., Doherty, M., Parmar, A., Menjak, I. B., Leighl, N. B., Agulnik, J., Lu, S., Han, Z., Cui, J., Zhang, L., Cheng, Y., Chen, G., Zhang, H., Yao, Y., Hu, C., Wang, Q., Zhang, X., Zhang, Y., Zhou, J., Ying, K., Fan, Y., Wang, Y., Wang, Z., Feng, J., Du, Y., Wu, L., Huang, C., Zhou, X., Perol, M., Domont, J., Lamour, C., Dutilh, J., Oulkhouir, Y., Westeel, V., Carmier, D., Coudert, B., Lagrange, A., Spaeth, D., Ropert, S., Christoph, D. C., Kern, J., Kopp, H.-G., Griesinger, F., Wiewrodt, R., Wermke, M., Wesseler, C., Mueller, A., Vogel, G., Lee, V., James Ho, C. M., Oscar Chan, S. H., Hung Lo, S., Jonathan Nyaw, S. F., Jacky Li, Y. C., Bar, J., Gottfried, M., Dudnik, J., Zer, A., Moskovitz, M., Wollner, M., Rotem, O., Shamai, S., Asna, N., Kamel, M., Novello, S., Di Costanzo, F., Doni, L., Mazzoni, F., Ferrau, F., de Marinis, F., Tonini, G., Galetta, D., Piantedosi, F., Vitiello, F., Kirita, K., Yoh, K., Takahashi, T., Ohe, Y., Hattori, Y., Okamoto, I., Kurata, T., Yoshioka, H., Saka, H., Oki, M., Kato, T., Tanaka, H., Kumagai, T., Inoue, T., Hida, T., Horio, Y., Teraoka, S., Ichihara, E., Kishi, K., Takaya, H., Takai, D., Kozuki, T., Kasahara, K., Tambo, Y., Hosomi, Y., Kondo, M., Ichiki, M., Takeoka, H., de la Mora Jimenez, E., Hernandez, C. A., Rodriguez Cid, J. R., Rodriguez, O. G. A., Han, J.-Y., Min, Y. J., Kim, D.-W., Park, K., Lee, S.-H., Lee, K. H., Lee, J.-S., Kang, J. H., Lee, D. H., Cho, E. K., Carcereny, E., Lopez, P. G., Tarruella, M. M., Rodriguez, L. P.-A., Vicente Baz, D., Font, E. F., Cobo-Dols, M., Ekman, S., Bergman, B., Ohman, R., Vikstrom, A., Yang, C.-H., Chiu, C.-H., Huang, H.-C., Yang, C.-T., Su, J., Chang, G.-C., Yang, T.-Y., Hsia, T.-C., Su, W.-C., Wu, S.-Y., Wang, C.-C., Lee, K.-Y., Lin, S.-H., Lin, C.-B., Lee, J.-H., Huang, C.-Y., Ahmed, S., Newsom-Davis, T., Baijal, S., Brock, J., Zaki, K., Shamash, J., Papadatos-Pastos, D., Jain, P., Jane Mackean, M., Kendall, S. D., Anderson, I., Costin, D., Hall, R., Campbell, N., Khan, S., Dowell, J., Mashru, S., Menon, S., Raza, A., Ge, L., Riely, G. J., Seetharamu, N., Stampleman, L., Subramanian, J., Wender, D. B., Natale, R. B., Zhu, V., Ignatius Ou, S.-H., Sanborn, R., & Evangelist, M. C.
- Venue
- Journal of Clinical Oncology
- Published
- 2024-12
- Volume
- 42
- Issue
- 34
- Pages
- 4029-4039
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4401742667
- Cited by
- 165
- References
- 7
- FWCI
- 40.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.